Dementia of the Alzheimer's type with delusions

3 trials 2 recruiting MedDRA PT
3 Registered trials
2 Recruiting
2 Unique sponsors
2 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Phase II: 3

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase II

3 trials
  • Intra-Cellular Therapies Inc. Commercial
    ITI-1284
    2024-513035-25-00 8 countries 2025 n=216
    Recruiting
  • Maplight Therapeutics Inc. Commercial
    FESOTERODINE, 5-[(1R,5R)-3-AZABICYCLO[3.1.0]HEXAN-1-YL]-3-METHYL-1,2,4-OXADIAZOLE
    2024-519820-26-00 9 countries 2026 n=78
    Recruiting
  • Maplight Therapeutics Inc. Commercial
    FESOTERODINE, 5-[(1R,5R)-3-AZABICYCLO[3.1.0]HEXAN-1-YL]-3-METHYL-1,2,4-OXADIAZOLE
    2025-521757-16-00 9 countries n=85
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Maplight Therapeutics Inc. Commercial 2 Phase II 1
Intra-Cellular Therapies Inc. Commercial 1 Phase II 1
New trials by year
2025
1
2026
1
← All indication landscapes